Author:
Starza Irene Della,Eckert Cornelia,Drandi Daniela,Cazzaniga Giovanni,
Abstract
AbstractAnalysis of immunoglobulin and T-cell receptor gene rearrangements by real-time quantitative polymerase chain reaction (RQ-PCR) is the gold standard for sensitive and accurate minimal residual disease (MRD) monitoring; it has been extensively standardized and guidelines have been developed within the EuroMRD consortium (www.euromrd.org). However, new generations of PCR-based methods are standing out as potential alternatives to RQ-PCR, such as digital PCR technology (dPCR), the third-generation implementation of conventional PCR, which has the potential to overcome some of the limitations of RQ-PCR such as allowing the absolute quantification of nucleic acid targets without the need for a calibration curve. During the last years, droplet digital PCR (ddPCR) technology has been compared to RQ-PCR in several hematologic malignancies showing its proficiency for MRD analysis. So far, no established guidelines for ddPCR MRD analysis and data interpretation have been defined and its potential is still under investigation. However, a major standardization effort is underway within the EuroMRD consortium (www.euromrd.org) for future application of ddPCR in standard clinical practice.
Reference25 articles.
1. Cazzaniga G, Biondi A (2005) Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology. Haematologica 90:382–390
2. Faderl S, O’Brien S, Pui C-H, Stock W, Wetzler M, Hoelzer D et al (2010) Adult acute lymphoblastic leukemia: concepts and strategies. Cancer 116:1165–1176
3. Gökbuget N, Raff R, Brüggemann M, Flohr T, Scheuring U, Pfeifer H et al (2004) Risk/MRD adapted GMALL trials in adult ALL. Ann Hematol 83:S129–S131
4. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Moricke A et al (2010) Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115:3206–3214
5. Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R et al (2013) Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol 14:199–109
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献